论文信息 - In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients - 字舞流文

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

Taiwo A. Togun | U. Dafni | J. Bordeaux | D. Rimm | A. Psyrri | G. Fountzilas | G. Pentheroudakis | V. Neumeister | D. Pectasides | D. Skarlos | V. Kotoula | M. Bobos | Huan Cheng | M. Vassilakopoulou | Mattheos Bobos